PLx Pharma (NASDAQ: PLXP) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.
Insider & Institutional Ownership
25.0% of PLx Pharma shares are owned by institutional investors. Comparatively, 8.0% of Dare Bioscience shares are owned by institutional investors. 47.7% of PLx Pharma shares are owned by insiders. Comparatively, 28.6% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
This table compares PLx Pharma and Dare Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares PLx Pharma and Dare Bioscience’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|PLx Pharma||N/A||N/A||-$21.32 million||N/A||N/A|
|Dare Bioscience||$760,000.00||7.88||-$39.30 million||N/A||N/A|
PLx Pharma has higher earnings, but lower revenue than Dare Bioscience.
Volatility & Risk
PLx Pharma has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 2.69, meaning that its share price is 169% more volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for PLx Pharma and Dare Bioscience, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
PLx Pharma currently has a consensus target price of $14.00, indicating a potential upside of 124.00%. Given PLx Pharma’s higher possible upside, analysts clearly believe PLx Pharma is more favorable than Dare Bioscience.
PLx Pharma beats Dare Bioscience on 7 of the 9 factors compared between the two stocks.
PLx Pharma Company Profile
PLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company’s lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.
Dare Bioscience Company Profile
Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.